Company intelligence / Profile preview

MicroDose Therapeutx

Monmouth Junction, New Jersey, United Stateslegistorm.com ↗

Ownership: Private
Development stage: Other

Overview

MicroDose developed proprietary dry powder inhaler and oral combination technologies. Its lead assets included a highly selective small molecule for IBS-C/chronic constipation ("MDT‑006", formerly "EPX‑16006") and partnered respiratory programs. The company was acquired by Teva in June 2013 before any independent product approvals or late-stage clinical results were published.

Therapeutic areas: NeurologyPulmonologyInfectious DiseasesGastroenterologyEndocrinology
Modalities: Small moleculeDeviceCombination product
Industry: Biotech

Partnerships

Merck & Co.: global license agreement for use of dry powder inhaler technology with Merck compounds ($32M+ milestones plus royalties)Novartis/Qdose joint venture—inhaled insulin programUniversity of Pittsburgh/U.S. Department of Defense—for nerve agent antidote device development

Beyond the preview

Go deeper on MicroDose Therapeutx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroDose Therapeutx.

Explore the full profile